Toxoplasmosis Treatment Market By Type (Acquired Toxoplasmosis, Congenital Toxoplasmosis), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global toxoplasmosis treatment market was valued at $683.11 million in 2021, and is projected to reach $1,093.88 million by 2031, registering a CAGR of 4.8% from 2022 to 2031. Toxoplasmosis is a disease that occurs due to Toxoplasma gondii parasite, which is one of the world's most common parasites. This infection usually occurs by eating undercooked contaminated meat, exposure from infected cat feces, or mother-to-child transmission during pregnancy. Toxoplasmosis may cause flu-like symptoms in some people, however majority of those infected never show any signs or symptoms.
The growth of global toxoplasmosis treatment market is majorly driven by increase in prevalence of foodborne illness. In addition, technological advancement in treatment and diagnosis for toxoplasmosis disease propels the market growth. Furthermore, increase in awareness regarding toxoplasmosis treatment in developed countries such as the U.S. further fuels the market growth.
In addition, increase in prevalence of HIV across the globe has increased the risk of toxoplasma gondii infection due to less immune response in HIV infected patients that lead to rise in demand for toxoplasmosis treatment and propels the market growth. For instance, according to the World Health Organization (WHO), by the end of 2021, around 38.4 million people were living with HIV across the globe, therefore it is expected to increase the prevalence of toxoplasmosis infection among the global population that drives the market growth.
Furthermore, surge in healthcare, industrial development, and investments by the government and private organizations in Asia-Pacific, along with rise in awareness regarding toxoplasmosis disease is anticipated to positively impact the market during the forecast period. Moreover, product launch for toxoplasmosis treatment by the key market players are the boosting factors for the market growth. For instance, Dr. Reddy's Laboratories Ltd. announced the launch of pyrimethamine tablet USP, 25 mg, approved by the U.S. Food and Drug Administration (USFDA) for the treatment of toxoplasmosis.
However, side effects of toxoplasmosis drugs and high cost of treatment hinder the market growth. Conversely, rise in product approvals for toxoplasmosis treatment is anticipated to provide lucrative opportunities to the market players.
The toxoplasmosis treatment market is segmented on the basis of type, route of administration, distribution channel, and region. By type, the market is categorized into acquired toxoplasmosis and congenital toxoplasmosis. On the basis of route of administration, the market is segregated into oral and parenteral. By distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global toxoplasmosis treatment market are Alvogen, Dr. Reddy's Laboratories Ltd., Kaiser Permanente, Mangalam Drugs and Organics Ltd., Manus Aktteva Biopharma LLP, Oakrum Pharma, Omicron pharmaceuticals, Teva Pharmaceutical Industries Ltd., Vyera Pharmaceuticals LLC, and Zorish Healthcare Private Limited.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the toxoplasmosis treatment market analysis from 2021 to 2031 to identify the prevailing toxoplasmosis treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the toxoplasmosis treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global toxoplasmosis treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Type
Acquired Toxoplasmosis
Congenital Toxoplasmosis
By Route of Administration
Oral
Parenteral
By Distribution Channel
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Arabia
Rest of LAMEA
Key Market Players
Alvogen
Dr Reddy's Laboratories Ltd.
Teva Pharmaceutical Industries Limited
Vyera Pharmaceuticals LLC
Mangalam Drugs and Organics Ltd.
Oakrum Pharma
Kaiser Permanente
Zorish Healthcare Private Limited
omicron pharmaceuticals
Manus Aktteva Biopharma LLP
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook